Within about a week in September, the Union Health Ministry made two moves that look separate but share a single instinct: shrinking the gap between what the rules say and what actually happens at the point where a patient meets a medicine or a treatment. One is a draft amendment to the Drugs Rules aimed at how prescription-only medicines are sold across pharmacy counters. The other is an advisory on stem-cell therapy, aimed at clinics offering treatments that have not been shown to work. Neither is a blanket ban, and both are easy to misread from a headline.
Move one: a draft rule for pharmacy counters
On 8 September 2026, the Ministry of Health and Family Welfare published a draft notification, G.S.R. 791(E), proposing amendments to the Drugs Rules, 1945. Its stated objective is to strengthen oversight of Schedule H, H1 and X drugs, and in particular to address concerns about unauthorised access to and sale of those medicines. According to the reporting, the proposal was first deliberated by the Drugs Consultative Committee and then circulated to the Drugs Technical Advisory Board, which recommended approval. The ministry has invited objections and suggestions from stakeholders and members of the public before anything becomes final.
The centrepiece, as reported, is a requirement that retail medical stores that supply these drugs install CCTV cameras. Reports say wholesalers are outside the requirement, and one account says recordings would have to be kept for at least three months. That last detail comes from a single report and should be treated as provisional until the notification text is consulted directly.
A draft is a proposal. Nothing changes at the pharmacy counter until the comment period ends and a final rule is notified.
What the three schedules mean
The schedules are categories in India's drug law, and they are stricter than most people realise. Schedule H covers medicines that may be sold only on the prescription of a registered medical practitioner. Schedule H1 is a tighter tier, including certain antibiotics and other drugs with a risk of misuse; pharmacies must keep a separate register recording the patient, the prescriber, the drug and the quantity, and preserve it for three years. Schedule X is stricter still, covering narcotic and psychotropic substances, with additional requirements around prescriptions, record-keeping and storage.
The trouble is that these controls already exist on paper. The debate is about enforcement. A prescription requirement is hard to police at thousands of small counters, and an informal sale of a prescription-only drug leaves little trace. CCTV is a way of creating that trace. Its stated purpose in the reports is to serve as an additional regulatory safeguard against sales without valid prescriptions.
The questions the draft raises
Three questions will likely dominate the comment period. The first is cost and practicality for small, independent pharmacies, especially in smaller towns, where margins are thin and a camera system, storage and maintenance are real expenses. The second is privacy: cameras at a pharmacy counter will capture customers buying medicines, some of them sensitive, and the draft will be scrutinised for how footage is stored and who may access it. The third is whether the requirement will be workable to enforce. Footage held by a shopkeeper only helps if inspectors are able to inspect it, and if there is a clear process when they do.
These are questions, not conclusions. The reports available do not set out the full text of the safeguards, and readers with a stake in the outcome, whether pharmacists or patients, will want to read the notification itself and file comments while the window is open.
Move two: an advisory on stem-cell therapy
On 16 September 2026, the Ministry issued an advisory to states and union territories that have adopted the Clinical Establishments (Registration and Regulation) Act, 2010. Its central message, as reported, is that stem-cell treatment may be offered as standard care only for the disease conditions or indications on the list approved by the Ministry. It specifically states that therapeutic use of any type of stem cell for autism should remain restricted to duly approved clinical trials, and that unproven interventions should not be offered as routine, standard or commercial services.
Context matters. Reporting links the advisory to a Supreme Court judgment of 30 January 2026 in Yash Charitable Trust & Ors. v. Union of India. Separately, the National Medical Commission was reported to have issued its own advisory on 5 September 2026, saying that stem-cell therapy may be offered as standard clinical care only for approved indications, and that administering, prescribing, promoting or advertising it outside those indications would amount to professional misconduct.
What is established, and what is not
It would be a mistake to read the advisory as a verdict against stem cells as such. Speaking to India TV News, Dr Prashant Mehta of Amrita Hospital, Faridabad, who heads the bone marrow transplant, CAR-T and cellular therapy programme, pointed out that stem-cell treatment has a long-established place in medicine. The clearest example is haematopoietic stem-cell transplantation, used for selected blood cancers and serious blood disorders. His caution, as reported, was about claims that go beyond what rigorous trials have shown, and he noted that the small randomised trials in autism cited in the discussion, involving 32 and 34 children, showed that the approach was feasible but did not establish that it works.
That distinction, between a therapy with proven uses and the same label stretched over conditions with no such evidence, is the core of the advisory. It is also the practical reality for families. Parents of children with autism, for example, are sometimes targeted by clinics that market cell-based treatments. The advisory says those should be available only inside approved trials, where patients are monitored and the evidence is collected.
The advisory does not say stem cells do not work. It says claims must match the evidence.
What patients and families can do
Neither move changes anything for a patient tomorrow, and neither is a substitute for a doctor's advice. But the direction of both suggests practical questions. If a clinic offers a stem-cell treatment, ask whether the use is on the government's approved list and whether it is part of a registered clinical trial. If it is a trial, ask who is running it and how participants are monitored. If it is described as standard care but the condition is not one for which the treatment is established, the advisory suggests it should not be offered as such. At a pharmacy, expect that some medicines, especially those in the stricter schedules, will not be handed over without a valid prescription, and that record-keeping and cameras may become part of the picture.
The bigger picture
Taken together, the two moves reflect a regulator trying to close the distance between paper and practice. In the first case, rules that already exist may be reinforced with a tool to monitor them. In the second, a legal framework that already existed is being restated so that states can act on it. Both depend on enforcement at the level of individual counters and clinics, and both will be judged on whether that enforcement actually happens. The draft rule is open for comment; the advisory is already in force in the sense that states are being asked to apply it. The next things to watch are the final text of the pharmacy rule and whether state authorities begin acting on the stem-cell advisory.
